知镜 Cognispect · 医学文献与研究工作台

Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1.

Mackie J, Sim S, Cominsky LY, Nigrovic PA, Romberg N.
Journal of human immunity · 2026-11-12 · PMID 43018475

文献摘要

The transcription factor (TF) SPI1 (historically called PU.1) is a critical pioneer TF and regulator of hematopoiesis. It exerts exquisitely dose-dependent and stage-specific control over lymphoid, myeloid, and central nervous system-resident lineages. Structurally characterized by an intrinsically disordered N-terminal transactivation region and a highly conserved C-terminal DNA-binding E26 transformation-specific domain, SPI1 can operate alone as a monomer, via homodimerization, through epigenetic interactions, and in context-dependent transcriptional partnerships. While early animal models established its essentiality for leukopoiesis, modern human genomics has unveiled direct links between altered SPI1 function and disease. Heterozygous loss-of-function germline variants cause PU.1-mediated agammaglobulinemia, whereas somatic mutations and/or regulatory alterations can drive hematologic malignancies. Dysregulated SPI1 activity is also implicated in autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, and neurodegenerative disorders. This review reconciles foundational murine paradigms with emerging human translational data, highlights current therapeutic landscapes, and projects how single-cell multi-omics and advanced gene editing may shape future directions in the SPI1 biomedical field.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。